Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Autor: Jhaveri KL; Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY., Lim E; Garvan Institute of Medical Research, St Vincent's Clinical School, University of New South Wales, Darlinghurst, NSW, Australia., Jeselsohn R; Dana-Farber Cancer Institute, Boston, MA., Ma CX; Washington University School of Medicine, St Louis, MO., Hamilton EP; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN., Osborne C; US Oncology Research, McKesson Specialty Health, The Woodlands, TX.; Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX., Bhave M; Emory University, Atlanta, GA., Kaufman PA; University of Vermont Cancer Center, Burlington, VT., Beck JT; Highlands Oncology Group, Springdale, AR., Manso Sanchez L; Hospital Universitario 12 de Octubre, Madrid, Spain., Parajuli R; University of California, Irvine, CA., Wang HC; China Medical University Hospital, Taichung, Taiwan., Tao JJ; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD., Im SA; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Harnden K; Inova Schar Cancer Institute, Fairfax, VA., Yonemori K; National Cancer Center Hospital, Tokyo, Japan., Dhakal A; University of Rochester Medical Center, Rochester, NY., Neven P; Universitaire Ziekenhuizen-Leuven Cancer Institute, Leuven, Belgium., Aftimos P; Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Institut Jules Bordet, Brussels, Belgium., Pierga JY; Institut Curie, Université Paris Cité, Paris, France., Lu YS; National Taiwan University Hospital, Taipei, Taiwan., Larson T; Minnesota Oncology/The US Oncology Network, Minneapolis, MN., Jerez Y; Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain., Sideras K; Mayo Clinic, Jacksonville, FL., Sohn J; Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim SB; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea., Saura C; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Bardia A; Massachusetts General Hospital, Boston, MA., Sammons SL; Dana-Farber Cancer Institute, Boston, MA.; Duke Cancer Institute, Duke University, Durham, NC., Bacchion F; Eli Lilly and Company, Indianapolis, IN., Li Y; Eli Lilly and Company, Indianapolis, IN., Yuen E; Eli Lilly and Company, Indianapolis, IN., Estrem ST; Eli Lilly and Company, Indianapolis, IN., Rodrik-Outmezguine V; Eli Lilly and Company, Indianapolis, IN., Nguyen B; Eli Lilly and Company, Indianapolis, IN., Ismail-Khan R; Eli Lilly and Company, Indianapolis, IN., Smyth L; Eli Lilly and Company, Indianapolis, IN., Beeram M; START Center for Cancer Care, San Antonio, TX.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Dec 10; Vol. 42 (35), pp. 4173-4186. Date of Electronic Publication: 2024 Sep 06.

Ultrasound in anti-CCP+ at-risk individuals without clinical synovitis: development of a novel 6-joint protocol for feasible risk prediction.

Autor: Di Matteo A; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., De Lorenzis E; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; Division of Rheumatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino-Gemelli IRCSS, Rome, Italy., Duquenne L; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Nam JL; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Garcia-Montoya L; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Harnden K; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Chowdhury R; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Wakefield RJ; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Emery P; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Mankia K; Rheumatology Department, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Aug 01; Vol. 63 (8), pp. 2213-2221.

Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study.

Autor: Garcia-Montoya L; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Rotherham General Hospital, Rotherham NHS Foundation Trust, Rotherham, UK., Kang J; School of Dentistry, University of Leeds, Leeds, UK., Duquenne L; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Di Matteo A; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Nam JL; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Harnden K; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Chowdhury R; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Mankia K; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Emery P; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address: p.emery@leeds.ac.uk.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2024 Feb; Vol. 6 (2), pp. e72-e80.

Predicting Inflammatory Arthritis in At-Risk Persons: Development of Scores for Risk Stratification.

Autor: Duquenne L; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Hensor EM; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Wilson M; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Garcia-Montoya L; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Nam JL; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Wu J; Leeds Institute for Data Analytics, University of Leeds, Leeds, and Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom (J.W.)., Harnden K; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Anioke IC; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, and Department of Medical Laboratory Sciences, University of Nigeria, Nigeria (I.C.A.)., Di Matteo A; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Chowdhury R; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Sidhu N; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Ponchel F; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom (F.P.)., Mankia K; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.)., Emery P; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (L.D., E.M.H., M.W., L.G., J.L.N., K.H., A.D.M., R.C., N.S., K.M., P.E.).

Publikováno v: Annals of internal medicine [Ann Intern Med] 2023 Aug; Vol. 176 (8), pp. 1027-1036. Date of Electronic Publication: 2023 Aug 01.

383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study

Autor: Jhaveri, K., Jeselsohn, R., Ma, C.X., Lim, E., Yonemori, K., Hamilton, E.P., Harnden, K., Im, S-A., Beck, T., Sammons, S., Bhave, M., Kaufman, P.A., Manich, C. Saura, Meniawy, T., Bacchion, F., Ismail-Khan, R., Li, Y., Estrem, S.T., Nguyen, B., Beeram, M.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S338-S339